Serum GA and esRAGE are novel predictors of long-term clinical outcomes in patients with type 2 diabetes and stable CAD. Increased serum GA and decreased esRAGE are associated with a poor prognosis in such patients (International Journal of Cardiology)
Diabetes News
Tag: Type 2 Diabetes
Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease
In clinical practice, a substantial proportion of elderly patients may be overtreated. RI is insufficiently taken into account when prescribing OAD (Diabetes, Metabolic Syndrome and Obesity)
Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials
These results suggest that the use of ‘basal-plus’ can achieve a good therapeutic response with a low risk of hypoglycemia and weight gain, regardless of a patient’s age or BMI (Primary Care Diabetes)
Contemporary Risk Estimates of Three HbA1c Variables for Myocardial Infarction in 101,799 Patients Following Diagnosis of Type 2 Diabetes
The two time-updated HbA1c variables show a stronger relation with MI than baseline HbA1c. The risk association between HbA1c and MI has decreased over time. In recently diagnosed patients with type 2 diabetes, an increased risk of MI exists at a current HbA1c of <6.0% (42 mmol/mol) (Diabetes Care)
Predictors of all-cause and cardiovascular disease mortality in type 2 diabetes: Diabetes Heart Study
This analysis highlights important demographic and clinical factors, notably CAC and albuminuria, which predict mortality in the general population of patients with T2D (Diabetology & Metabolic Syndrome)
The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus
Vitamin D deficiency is more common in diabetic patients with nephropathy. When microvascular complications were evaluated, vitamin D levels were found to be lower in patients in whom these complications were more severe. Vitamin D deficiency is therefore associated with microvascular complications in diabetic patients (BMC Endocrine Disorders)
Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment
Among obese participants with T2DM, bariatric surgery with 2 years of an adjunctive low-level lifestyle intervention resulted in more disease remission than did lifestyle intervention alone (JAMA)
Insulin mediated improvement in glycemic control in elderly with type 2 diabetes mellitus can improve depressive symptoms and does not seem to impair health-related quality of life
Insulin therapy in elderly people with type 2 diabetes can lead to an improvement of depressive symptoms and does not seem to affect negatively HRQoL of the participants (Diabetology & Metabolic Syndrome)
Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes
This guidance is intended to help both general and specialist practitioners make informed choices and provide optimal care for patients with T2D (Diabetes Therapy)
Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents
The results show that in a patient population with sub-optimal glycemic control at baseline, and a low target achievement rate together with a low rate of hypoglycemia, differences in the patient reported outcomes evaluated in this study were negligible between insulin glargine and NPH insulin (Health and Quality of Life Outcomes)
Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin
A Systematic Review and Meta-Analysis of Population Based Studies (PLOS ONE)
Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
Exposure to insulin glargine in long standing T2D patients, who reach the point of adding or switching to insulin after a certain (usually long) time on OADs alone, is safe and maybe even beneficial in terms of major fatal cardiovascular events (Journal of Diabetes Research)
Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes
These results support the hypothesis that iron-mediated oxidative stress may be a mechanism linking poor glycaemic control with vascular dysfunction in type 2 diabetes (Journal of Diabetes and Its Complications)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events (NEJM)
Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks (Boehringer Ingelheim)
Lilly’s Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes
Data from Phase III Clinical Trial Program Presented at the 2015 American Diabetes Association Scientific Sessions (Lilly)
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Insulin is a common treatment option for many patients with type 2 diabetes, and is generally used late in the natural history of the disease (The Lancet Diabetes & Endocrinology)
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
After nearly 10 years of follow-up, patients with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had 8.6 fewer major cardiovascular events per 1000 person-years than those assigned to standard therapy, but no improvement was seen in the rate of overall survival (NEJM)
Design of stepwise screening for prediabetes and type 2 diabetes based on costs and cases detected
Our applied method makes it possible to identify a range of efficient cut-offs where higher detection rates can be achieved at an additional cost per detected patient. This enables decision makers to choose an optimal cut-off based on their willingness to pay for additional detected patients (Journal of Clinical Endocrinology Epidemiology)
The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes
CV in CGM and all parameters of HbA1c variability were independently associated with the presence of CAN in patients with inadequately controlled type 2 diabetes requiring CGM (Cardiovascular Diabetology)
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- 63
- Next Page »
Glycosmedia is also available as an App: